Subscribe to An Active Surveillance, Post-Authorisation Study to Characterize the Safety of Tofacitinib in Patients with Moderately to Severely Active Ulcerative Colitis in the Real-World Setting Using Data from the Swedish Quality Register for Inflammatory Bowel Disease (SWIBREG)